TH.TO - Theratechnologies Inc.

Toronto - Toronto Real Time Price. Currency in CAD
1.2500
+0.0900 (+7.76%)
At close: 03:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.1600
Open1.1800
Bid1.2300 x 0
Ask1.2500 x 0
Day's Range1.1800 - 1.3500
52 Week Range1.0000 - 3.7500
Volume30,770
Avg. Volume16,571
Market Cap121.008M
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)-0.7400
Earnings DateJul 12, 2023 - Jul 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.44
  • GlobeNewswire

    Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide

    Phase 1 trial to resume with weekly dosing, a focus on patients with ovarian cancer and refined patient selectionJune 13 call for investors and analysts with trial investigators to provide insights on safety and efficacy data presented at ASCO 2023 that informed protocol updateThis news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021, to its short form base shelf prospectus dated December 14, 2021. MONTREAL, June 02,

  • GlobeNewswire

    Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023

    Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses (PR) and seven patients with prolonged stable disease (SD) Efficacy and tolerability data from dose escalation and expansion results inform protocol amendment designed to improve therapeutic window of sudocetaxel zendusortide MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the develop

  • CNW Group

    Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc.

    This press release is being disseminated as required by National Instrument 62–103 - The Early Warning System and Related Take Over Bids and Insider Reporting Issuers in connection with the filing of an early warning report (the "Early Warning Report") regarding the acquisition of securities of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (the "Issuer"), with its head office located at 2015, rue Peel, 11e étage, Montréal, PQ H3A 1T8, by Soleus Capital Master Fund, L.P. ("Soleus Master Fund"),

  • GlobeNewswire

    Theratechnologies Reports on its Annual Meeting of Shareholders

    MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. As part of the meeting, Paul Lévesque, President and CEO of Theratechnologies confirmed that the amended protocol for the Phase 1 clinical trial studying the Com

  • GlobeNewswire

    Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison

    First-of-its-Kind Study in HIV Compares Ibalizumab Clinical Trial Experience to Matched Real-World Non-Ibalizumab OPERA® CohortData Presented at ACTHIV™ Conference Highlight Improved Clinical Outcomes of Ibalizumab for Heavily Treatment-Experienced People with HIV MONTREAL, May 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, to

  • Simply Wall St.

    Theratechnologies Inc.'s (TSE:TH) Business And Shares Still Trailing The Industry

    With a price-to-sales (or "P/S") ratio of 1.1x Theratechnologies Inc. ( TSE:TH ) may be sending bullish signals at the...

  • Baystreet

    Stocks in play: Theratechnologies Inc.

    Presented preclinical data that demonstrate the potential utility of its lead investigational peptide ...

  • GlobeNewswire

    Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies

    Preclinical data suggests that sudocetaxel zendusortide can induce immune cell infiltration in “cold” tumors and improve efficacy for PD-L1 checkpoint inhibitor Additional in vivo data demonstrate significant activity of sudocetaxel zendusortide against SORT1+ triple-negative (TNBC) and HER2+ breast cancersHigh expression of SORT1 in multiple solid tumor types further supports rationale for targeted therapy with sudocetaxel zendusortide MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnolog

  • Newsfile

    Theratechnologies to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

    Montreal, Quebec--(Newsfile Corp. - April 18, 2023) - Theratechnologies (NASDAQ: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 25 and 26 at the Metro Toronto Convention Centre. Dates:Tuesday April 25, 2023-Wednesday April 26, 2023Time:8:30 AM-4:30 PM ETLocation: Metro Toronto Convention Centre, North Building

  • GlobeNewswire

    Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023

    Q1 2023 Consolidated Revenue Grew 7%, Supported by 9% Growth in EGRIFTA SV® Revenue and 5% Growth in Trogarzo® Revenue Revised Sudocetaxel Zendusortide (TH1902) Phase 1 Trial Protocol Expected to be Filed by End of April FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19% MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biop

  • GlobeNewswire

    Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update

    MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12, 2023. The conference call will be held on Wednesday, April 12, 2023, hosted by Mr. Paul Lévesque, President and Chief Executive Officer, and begin at 8:30 a.m

  • GlobeNewswire

    Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model

    Data show that sudocetaxel zendusortide (TH1902) can induce tumor infiltrating lymphocytes and potentiate anti-PD-L1 immunotherapy in a melanoma mouse model Two other studies highlight activity of TH1902 in SORT1+ triple-negative and HER2+ breast cancers, as well as high expression of SORT1 in various tumor types, compared with healthy tissues MONTREAL, March 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical c

  • GlobeNewswire

    Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price

    MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated March 3, 2023, advising that the Company was not in compliance with Listing Rule 5550(a)(2) as the bid price of the Company’s listed secur

  • Simply Wall St.

    Theratechnologies Full Year 2022 Earnings: EPS Misses Expectations

    Theratechnologies ( TSE:TH ) Full Year 2022 Results Key Financial Results Revenue: US$80.1m (up 15% from FY 2021). Net...

  • GlobeNewswire

    Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022

    Q4 2022 consolidated revenue growth of 14.2% to $21.4 millionFY2022 revenue totaled $80.1 million or growth of ~15%, in line with guidanceFY2023 operating plan to focus on achieving positive Adjusted EBITDA1 by year end based on commercial business growth and tighter budget controlsFY2023 revenue guidance range set between $90 million and $95 million MONTREAL, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceut

  • GlobeNewswire

    Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management

    Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the developm

  • GlobeNewswire

    Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV

    Presentation at Conference on Retroviruses and Opportunistic Infections (CROI) demonstrates association between excess visceral abdominal fat (EVAF) reduction and decreased prevalence of metabolic syndrome with tesamorelin treatmentData provide further evidence of potential utility of tesamorelin in addressing metabolic syndrome and complement research in fatty liver diseases MONTREAL, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASD

  • GlobeNewswire

    Theratechnologies Announces Path to Resume TH1902 Clinical Development

    MONTREAL, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology clinical trial with the goal of a timely re-submission to the United States Food and Drug Administration (FDA). Following a voluntary pause in the study’s enrollment on

  • GlobeNewswire

    Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

    MONTREAL, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. The conference call will be held at 8:30 a.m. (ET) on February 28, 2023, to discuss the results and recent business updates. The c

  • GlobeNewswire

    Open Letter to Shareholders from CEO Paul Levesque

    Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key ObjectivesFY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidanceFY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash flow from operating activitiesFY2023 operating plan to focus on achieving positive EBITDA1 in the near-term based on commercial business growth and new asset opportunities

  • Simply Wall St.

    Shareholders in Theratechnologies (TSE:TH) are in the red if they invested five years ago

    Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held...

  • GlobeNewswire

    Theratechnologies Announces Update from Ongoing TH1902 Study

    This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021.MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of p

  • GlobeNewswire

    Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays

    Poster for presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics enhances understanding of SORT1 expression in healthy and tumor tissuesExtensive dataset underscores potential of SORT1 as a new anticancer therapeutic target MONTREAL, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies re

  • GlobeNewswire

    Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update

    - Q3 2022 Consolidated Revenue Growth of 17% to $20.8 million - Q3 2022 North American Revenue Growth of 19% - TH1902 Phase 1 basket trial proceeding as planned - On track to meet FY2022 Revenue Guidance $79 - $82 million MONTREAL, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and finan

  • GlobeNewswire

    Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium

    MONTREAL, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of SORT1, the target for Theratechnologies’ oncology platform, in several cancer types. The data will be presented in a poster session at the 34th joint symposium of t